METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets genetic fatty liver disease in landmark trial
Disease control Not yet recruitingThis study tests an experimental drug, ALN-PNP, alone or with a weight-loss drug (like tirzepatide), in 204 adults with a genetic form of fatty liver disease (MASLD). The goal is to see if lowering a specific protein (PNPLA3) can reduce liver fat. Participants must have a specifi…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
DASH diet tested as a way to control fatty liver in kids
Disease control Not yet recruitingThis study looks at whether the DASH diet (a heart-healthy eating plan) can improve liver health in children with a type of fatty liver disease called MASLD. About 88 children aged 11 to 18 will either follow the DASH diet or continue their usual eating habits for 12 weeks. Resea…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: NA • Sponsor: Antalya Training and Research Hospital • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Could a common supplement stop liver cancer before it starts?
Prevention Not yet recruitingThis study tests whether a natural supplement called SAMe can help prevent liver cancer in people with advanced fatty liver disease (MASLD) and cirrhosis. About 94 adults will receive either SAMe or a placebo for 12 months. Researchers will measure changes in a blood test that pr…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE2 • Sponsor: Cedars-Sinai Medical Center • Aim: Prevention
Last updated May 19, 2026 12:00 UTC
-
New drug miricorilant tested for fatty liver disease safety
Knowledge-focused Not yet recruitingThis early-stage study tests the safety and how the body processes the drug miricorilant in 15 adults with MASH, a serious fatty liver condition. Participants will take the drug and be monitored for side effects and drug levels in the blood. The goal is to gather information for …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Knowledge-focused
Last updated May 18, 2026 12:08 UTC